Climb Bio, Inc. develops therapeutics for patients with immune-mediated diseases. News about Climb Bio centers on its clinical-stage monoclonal antibody pipeline, including budoprutug, an anti-CD19 antibody for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy.
Recurring updates include clinical development progress, formulation data, regulatory actions such as FDA Fast Track Designation for budoprutug in primary membranous nephropathy, R&D presentations, business updates and operating results. Company announcements also cover financing activity, governance changes and investor communications tied to its biotechnology development strategy.
Climb Bio (Nasdaq: CLYM) reported topline Phase 1 subcutaneous (SC) data for budoprutug showing robust B-cell depletion in healthy volunteers, comparable to IV at matched doses, and that SC was generally safe and well-tolerated. The company received Fast Track designation for pMN and expects initial clinical data across ITP (June 2026), pMN (Q4 2026), and SLE (Q4 2026).
Climb is advancing budoprutug (anti-CD19 mAb) in parallel IV and SC programs across pMN, ITP, and SLE with biomarker-driven designs and a webcast held May 5, 2026.
Climb Bio (Nasdaq: CLYM) entered a private placement to raise approximately $110.0 million in gross proceeds, expected to close on or about April 29, 2026, subject to customary closing conditions.
The company is selling 9,481,000 common shares at $9.50 per share and issued pre-funded warrants to purchase up to 2,106,000 shares at $9.4999 each (exercise price $0.0001). Placement agents include Leerink Partners and Piper Sandler; several institutional investors participated. Climb Bio agreed to file a resale registration statement with the SEC within 45 days after closing.
Climb Bio (Nasdaq: CLYM) will host an R&D Spotlight webcast on May 5, 2026 at 8:00 a.m. ET focused on budoprutug, an anti-CD19 monoclonal antibody for B-cell mediated diseases. The event will cover target rationale, clinical study design, dose selection, and development strategy.
Speakers include Climb Bio management and David Jayne, MD, Professor of Clinical Autoimmunity at the University of Cambridge. A replay will be available on the company's investor website about two hours after the live webcast and archived for at least 30 days.
Climb Bio (Nasdaq: CLYM) announced FDA Fast Track Designation for budoprutug to treat primary membranous nephropathy (pMN).
Budoprutug showed complete peripheral B-cell depletion in 100% (5/5) of Phase 1b patients, serologic remission in 3/3 evaluable patients, and complete/partial clinical remission in 5/5 by week 48. A global Phase 2 study (PrisMN) is enrolling; initial data expected H2 2026.
Climb Bio (Nasdaq: CLYM) reported Q4 and full-year 2025 results and clinical updates on March 5, 2026. The company ended 2025 with $160.7 million in cash and expects runway into 2028. Multiple budoprutug trials are underway, a subcutaneous dosing study completed, and several initial data readouts are expected across 2026.
CLYM116 Phase 1 enrollment continues with initial healthy-volunteer data anticipated mid-2026; IND clearance obtained in China for a parallel SLE study.
Climb Bio (Nasdaq: CLYM) announced that its executive team will present at three investor conferences in Feb–Mar 2026: Guggenheim Emerging Outlook: Biotech Summit on Feb 12, Oppenheimer Healthcare Life Sciences on Feb 25, and Leerink Global Healthcare on Mar 9.
The presentations are fireside chats with live webcasts available via the company’s Investors & Media website; replays will be posted about two hours after each event and archived for at least 30 days.
Climb Bio (NASDAQ: CLYM) reported clinical and corporate progress and refreshed guidance on Jan 8, 2026. Key program updates include first patient dosed in the PrisMN Phase 2 trial for primary membranous nephropathy and ongoing dosing in budoprutug Phase 1b/2a ITP and Phase 1b SLE trials, plus IND clearance for a China SLE trial. First cohorts were dosed in a subcutaneous budoprutug Phase 1 healthy volunteer study. CLYM116 advanced into a Phase 1 healthy volunteer study after an in-license and FPI; partner Mabworks cleared a China IND. The company reported 20 regulatory clearances, activation of 45 trial sites, and cash runway expected into 2028. Multiple initial data readouts are anticipated across budoprutug and CLYM116 in 2026.
Climb Bio (Nasdaq: CLYM) granted an inducement equity award under its 2025 Inducement Plan to one new employee on November 24, 2025 pursuant to Nasdaq Listing Rule 5635(c)(4).
The award is a non-statutory stock option for 120,000 shares at an exercise price of $1.76 per share (equal to the Nasdaq closing price on November 24, 2025), with a 10-year term and four-year vesting: 25% after one year and the remainder in 36 equal monthly installments, subject to continued service and the terms of the award agreement and the 2025 Inducement Plan, as amended.
Climb Bio (NASDAQ: CLYM) reported Q3 2025 results and clinical progress on Nov 6, 2025. The company held $175.8 million in cash, cash equivalents and marketable securities as of Sept 30, 2025, which management expects will fund operations through 2027. Key clinical programs advanced: the PrisMN Phase 2 trial in primary membranous nephropathy has been initiated; a subcutaneous Phase 1 for budoprutug is enrolling with initial data expected H1 2026; ITP and SLE Phase 1b/2a trials expect initial data H2 2026. CLYM116 received regulatory clearance for Phase 1 dosing, with first subject anticipated by year-end 2025 and initial data mid-2026. Q3 operating items: R&D $9.1M, G&A $5.8M, other income $2.0M.
Leadership strengthened with appointments including Susan Altschuller, Ph.D., MBA as CFO.
Climb Bio (Nasdaq: CLYM) announced that executives will participate in three investor conferences in November–December 2025: Guggenheim's 2nd Annual Healthcare Innovation Conference in Boston on Nov 10, 2025 at 11:30 a.m. ET, Baird Biotech Discovery Series (virtual) on Nov 18, 2025 at 1:30 p.m. ET, and Piper Sandler’s 37th Annual Healthcare Conference in New York on Dec 2, 2025 at 9:30 a.m. ET.
Each appearance will include fireside chats; select events include one-on-one investor meetings. Live webcasts and replay recordings will be available via the Investors & Media section of the Climb Bio website and will be archived for at least 30 days.